Münevver Demir1, Sonja Lang2, Phillipp Hartmann3, Yi Duan4, Anna Martin5, Yukiko Miyamoto4, Marina Bondareva6, Xinlian Zhang7, Yanhan Wang4, Philipp Kasper5, Corinna Bang8, Christoph Roderburg9, Frank Tacke1, Hans-Michael Steffen5, Tobias Goeser5, Andrey Kruglov6, Lars Eckmann4, Peter Stärkel10, Derrick E Fouts11, Bernd Schnabl12. 1. Department of Hepatology and Gastroenterology, Campus Virchow Clinic and Campus Charité Mitte, Charité University Medicine, Berlin, Germany. 2. University of Cologne, Faculty of Medicine, and University Hospital Cologne, Department of Gastroenterology and Hepatology, Cologne, Germany; Department of Medicine, University of California San Diego, La Jolla, CA, USA. 3. Department of Medicine, University of California San Diego, La Jolla, CA, USA; Department of Pediatrics, University of California San Diego, La Jolla, CA, USA. 4. Department of Medicine, University of California San Diego, La Jolla, CA, USA. 5. University of Cologne, Faculty of Medicine, and University Hospital Cologne, Department of Gastroenterology and Hepatology, Cologne, Germany. 6. Belozerskiy Research Institute for Physical and Chemical Biology and Faculty of Bioengineering and Bioinformatics, M.V. Lomonosov Moscow State University, Moscow, 119991, Russia; Chronic Inflammation Lab, German Rheumatism Research Center, a Leibniz Institute, Berlin, Germany. 7. Division of Biostatistics and Bioinformatics, Herbert Wertheim School of Public Health and Human Longevity Science, University of California San Diego, La Jolla, CA, USA. 8. Institute of Clinical Molecular Biology, Christian-Albrechts-University of Kiel, 24105 Kiel, Germany. 9. Department of Hepatology and Gastroenterology, Campus Virchow Clinic and Campus Charité Mitte, Charité University Medicine, Berlin, Germany; Clinic for Gastroenterology, Hepatology and Infectious Diseases, University Hospital Düsseldorf, Medical Faculty of Heinrich Heine University Düsseldorf, Düsseldorf, Germany. 10. St. Luc University Hospital, Université Catholique de Louvain, Brussels, Belgium. 11. Department of Genomic Medicine, J. Craig Venter Institute, Rockville, MD, USA. 12. Department of Medicine, University of California San Diego, La Jolla, CA, USA; Department of Medicine, VA San Diego Healthcare System, San Diego, CA, USA. Electronic address: beschnabl@ucsd.edu.
Abstract
BACKGROUND & AIMS: Studies investigating the gut-liver axis have largely focused on bacteria, whereas little is known about commensal fungi. We characterized fecal fungi in patients with non-alcoholic fatty liver disease (NAFLD) and investigated their role in a fecal microbiome-humanized mouse model of Western diet-induced steatohepatitis. METHODS: We performed fungal internal transcribed spacer 2 sequencing using fecal samples from 78 patients with NAFLD, 16 controls and 73 patients with alcohol use disorder. Anti-Candida albicans (C. albicans) IgG was measured in blood samples from 17 controls and 79 patients with NAFLD. Songbird, a novel multinominal regression tool, was used to investigate mycobiome changes. Germ-free mice were colonized with feces from patients with non-alcoholic steatohepatitis (NASH), fed a Western diet for 20 weeks and treated with the antifungal amphotericin B. RESULTS: The presence of non-obese NASH or F2-F4 fibrosis was associated with a distinct fecal mycobiome signature. Changes were characterized by an increased log-ratio for Mucor sp./Saccharomyces cerevisiae (S. cerevisiae) in patients with NASH and F2-F4 fibrosis. The C. albicans/S. cerevisiae log-ratio was significantly higher in non-obese patients with NASH when compared with non-obese patients with NAFL or controls. We observed a different fecal mycobiome composition in patients with NAFLD and advanced fibrosis compared to those with alcohol use disorder and advanced fibrosis. Plasma anti-C. albicans IgG was increased in patients with NAFLD and advanced fibrosis. Gnotobiotic mice, colonized with human NASH feces and treated with amphotericin B were protected from Western diet-induced steatohepatitis. CONCLUSIONS: Non-obese patients with NAFLD and more advanced disease have a different fecal mycobiome composition to those with mild disease. Antifungal treatment ameliorates diet-induced steatohepatitis in mice. Intestinal fungi could be an attractive target to attenuate NASH. LAY SUMMARY: Non-alcoholic fatty liver disease is one of the most common chronic liver diseases and is associated with changes in the fecal bacterial microbiome. We show that patients with non-alcoholic fatty liver disease and more severe disease stages have a specific composition of fecal fungi and an increased systemic immune response to Candida albicans. In a fecal microbiome-humanized mouse model of Western diet-induced steatohepatitis, we show that treatment with antifungals reduces liver damage. Published by Elsevier B.V.
BACKGROUND & AIMS: Studies investigating the gut-liver axis have largely focused on bacteria, whereas little is known about commensal fungi. We characterized fecal fungi in patients with non-alcoholic fatty liver disease (NAFLD) and investigated their role in a fecal microbiome-humanized mouse model of Western diet-induced steatohepatitis. METHODS: We performed fungal internal transcribed spacer 2 sequencing using fecal samples from 78 patients with NAFLD, 16 controls and 73 patients with alcohol use disorder. Anti-Candida albicans (C. albicans) IgG was measured in blood samples from 17 controls and 79 patients with NAFLD. Songbird, a novel multinominal regression tool, was used to investigate mycobiome changes. Germ-free mice were colonized with feces from patients with non-alcoholic steatohepatitis (NASH), fed a Western diet for 20 weeks and treated with the antifungal amphotericin B. RESULTS: The presence of non-obese NASH or F2-F4 fibrosis was associated with a distinct fecal mycobiome signature. Changes were characterized by an increased log-ratio for Mucor sp./Saccharomyces cerevisiae (S. cerevisiae) in patients with NASH and F2-F4 fibrosis. The C. albicans/S. cerevisiae log-ratio was significantly higher in non-obese patients with NASH when compared with non-obese patients with NAFL or controls. We observed a different fecal mycobiome composition in patients with NAFLD and advanced fibrosis compared to those with alcohol use disorder and advanced fibrosis. Plasma anti-C. albicans IgG was increased in patients with NAFLD and advanced fibrosis. Gnotobiotic mice, colonized with human NASH feces and treated with amphotericin B were protected from Western diet-induced steatohepatitis. CONCLUSIONS: Non-obese patients with NAFLD and more advanced disease have a different fecal mycobiome composition to those with mild disease. Antifungal treatment ameliorates diet-induced steatohepatitis in mice. Intestinal fungi could be an attractive target to attenuate NASH. LAY SUMMARY: Non-alcoholic fatty liver disease is one of the most common chronic liver diseases and is associated with changes in the fecal bacterial microbiome. We show that patients with non-alcoholic fatty liver disease and more severe disease stages have a specific composition of fecal fungi and an increased systemic immune response to Candida albicans. In a fecal microbiome-humanized mouse model of Western diet-induced steatohepatitis, we show that treatment with antifungals reduces liver damage. Published by Elsevier B.V.
Entities:
Keywords:
Fungi; NAFLD; NASH; gut pathogens; metagenomics; microbiome; microbiota
Authors: Sonja Lang; Yi Duan; Jinyuan Liu; Manolito G Torralba; Claire Kuelbs; Meritxell Ventura-Cots; Juan G Abraldes; Francisco Bosques-Padilla; Elizabeth C Verna; Robert S Brown; Victor Vargas; Jose Altamirano; Juan Caballería; Debbie Shawcross; Michael R Lucey; Alexandre Louvet; Philippe Mathurin; Guadalupe Garcia-Tsao; Samuel B Ho; Xin M Tu; Ramon Bataller; Peter Stärkel; Derrick E Fouts; Bernd Schnabl Journal: Hepatology Date: 2019-08-20 Impact factor: 17.425
Authors: Vincent Wai-Sun Wong; Grace Lai-Hung Wong; Paul Cheung-Lung Choi; Anthony Wing-Hung Chan; Mia Ka-Po Li; Hoi-Yun Chan; Angel Mei-Ling Chim; Jun Yu; Joseph Jao-Yiu Sung; Henry Lik-Yuen Chan Journal: Gut Date: 2010-07 Impact factor: 23.059
Authors: Sara Lemoinne; Astrid Kemgang; Karima Ben Belkacem; Marjolène Straube; Sarah Jegou; Christophe Corpechot; Olivier Chazouillères; Chantal Housset; Harry Sokol Journal: Gut Date: 2019-04-19 Impact factor: 23.059
Authors: An-Ming Yang; Tatsuo Inamine; Katrin Hochrath; Peng Chen; Lirui Wang; Cristina Llorente; Sena Bluemel; Phillipp Hartmann; Jun Xu; Yukinori Koyama; Tatiana Kisseleva; Manolito G Torralba; Kelvin Moncera; Karen Beeri; Chien-Sheng Chen; Kim Freese; Claus Hellerbrand; Serene Ml Lee; Hal M Hoffman; Wajahat Z Mehal; Guadalupe Garcia-Tsao; Ece A Mutlu; Ali Keshavarzian; Gordon D Brown; Samuel B Ho; Ramon Bataller; Peter Stärkel; Derrick E Fouts; Bernd Schnabl Journal: J Clin Invest Date: 2017-05-22 Impact factor: 19.456
Authors: Marie van der Merwe; Sunita Sharma; Jade L Caldwell; Nicholas J Smith; Charles K Gomes; Richard J Bloomer; Randal K Buddington; Joseph F Pierre Journal: Curr Dev Nutr Date: 2020-01-03